Imatinib Mesylate Tablet, Film Coated
Product Images NDC 51407-269

8 FDA label images from Golden State Medical Supply, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 51407-269). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib Mesylate Structural Formula (Image 01)

Imatinib Mesylate Structural Formula (Image 01)
Chemical structure of imatinib mesylate, the active ingredient in Imatinib Mesylate tablets. The diagram shows the molecular arrangement of atoms including aromatic rings and sulfonate group characteristic of the mesylate salt form.*
FDA Label Image

Progression Free Survival (itt Principle) (Image 02)

Progression Free Survival (itt Principle) (Image 02)
A Kaplan-Meier curve depicting percentage without progression over months since randomization for two groups: imatinib arm (solid line) and IFN+Ara-C arm (dashed line). The chart includes patient numbers with progression, censored at discontinuation, and censored at last follow-up for each group, along with a hazard ratio (0.378) and p-value (<0.0001) from the log-rank test.*
FDA Label Image

Time To Progression To Ap Or Bc (itt Principle) (Image 03)

Time To Progression To Ap Or Bc (itt Principle) (Image 03)
A Kaplan-Meier survival curve chart comparing the percentage of patients without progression to AP or BC over months since randomization between two treatment arms: Imatinib arm (solid line) and IFN+Ara-C arm (dashed line). The chart includes patient numbers, hazard ratio with confidence interval, and statistical significance data.*
FDA Label Image

Study 1 Recurrence-free Survival (itt Population) (Image 04)

Study 1 Recurrence-free Survival (itt Population) (Image 04)
A Kaplan-Meier plot showing the percentage of patients without progression over months since randomization comparing Imatinib versus IFN plus Ara-C treatment arms. The chart includes the number of patients at risk and statistical values such as hazard ratio with 95% confidence intervals and the log-rank test p-value.*
FDA Label Image

Study 2 Recurrence-free Survival (itt Population) (Image 05)

Study 2 Recurrence-free Survival (itt Population) (Image 05)
A Kaplan-Meier survival curve comparing the percentage of patients without progression to AP or BC over 72 months since randomization in two treatment arms: Imatinib and IFN+Ara-C. The graph includes patient counts, hazard ratio, confidence interval, and a statistical significance value.*
FDA Label Image

Study 2 Overall Survival (itt Population) (Image 06)

Study 2 Overall Survival (itt Population) (Image 06)
A Kaplan-Meier survival curve chart depicting the probability of overall survival over time in months for two groups taking Imatinib at different durations (12 months and 36 months). The vertical axis shows survival probability percentage, and the horizontal axis shows survival time in months up to 84 months. The chart includes hazard ratio and statistical significance values, with censored observations marked.*
FDA Label Image

51407-269-90lb (IMATINIB MESYLATE 100MG TAB)

51407-269-90lb (IMATINIB MESYLATE 100MG TAB)
Imatinib Mesylate 100 mg film-coated tablets label from Golden State Medical Supply, Inc. The label shows the product name, strength (100 mg), and quantity (90 tablets). It includes storage instructions, dosage reference, and safety warnings, along with a barcode and lot/expiration details section.*
FDA Label Image

51407-270-30lb (IMATINIB MESYLATE 400MG TAB)

51407-270-30lb (IMATINIB MESYLATE 400MG TAB)
Label for Imatinib Mesylate Tablets 400 mg by Golden State Medical Supply, Inc. The label indicates a 30-tablet prescription package. It includes dosage strength, NDC 51407-270-30, barcode, and storage instructions, emphasizing moisture protection and child-resistant packaging. Marketing address and revision date 09/23 are also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.